Bicycle Therapeutics Reveals Updated Clinical Results Across Oncology Pipeline

(RTTNews) - Bicycle Therapeutics plc. (BCYC) announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) BT7480 in advanced solid tumors.

The company also shared an analysis of peripheral neuropathy, a key adverse event of interest associated with monomethyl auristatin E (MMAE)-based drug conjugates, in patients treated with BTC molecules.

The company noted that the data will be presented during a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona today.

The updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), an 11.1-month median duration of response, and a generally well-tolerated safety profile.

EphA2-targeting BT5528 demonstrated an emerging differentiated safety profile and antitumor activity in patients with advanced solid tumors, including a 45% ORR in the mUC 6.5 mg/m² every two weeks dose expansion cohort.

Monotherapy with Bicycle Toxin Conjugates zelenectide pevedotin and BT5528 was associated with a relatively low frequency and severity of treatment-related peripheral neuropathy, allowing most patients to continue therapy without modification.

BT7480 showed a favorable safety profile and preliminary antitumor activity in advanced Nectin-4-associated solid tumors.

For More Such Health News, visit rttnews.com.